Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Expert Review of Cardiovascular Therapy|November 4, 2006
Effective treatment of hypertension by AT(1) receptor antagonism: the past and future of telmisartanMatthias Goebel, Markus Clemenz, Thomas Unger
Chemmedchem|February 7, 2009
Characterization of new PPARgamma agonists: analysis of telmisartan's structural componentsMatthias Goebel, Markus Clemenz, Bart Staels, et al.
Biochemical and Biophysical Research Communications|November 15, 2007
Insulin facilitates monocyte migration: a possible link to tissue inflammation in insulin-resistanceKai Kappert, Heike Meyborg, Markus Clemenz, et al.
American Journal of Physiology. Heart and Circulatory Physiology|May 14, 2013
Sexual dimorphism in obesity-mediated left ventricular hypertrophyChristian Böhm, Verena Benz, Markus Clemenz, et al.
Cardiovascular Diabetology|October 20, 2010
PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese miceAnna Foryst-Ludwig, Martin Hartge, Markus Clemenz, et al.
Hypertension (Dallas, Tex. : 1979)|June 9, 2005
PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectinRonald Clasen, Michael Schupp, Anna Foryst-Ludwig, et al.
Hypertension (Dallas, Tex. : 1979)|December 26, 2007
Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gammaDaniel Walcher, Katharina Hess, Philipp Heinz, et al.
Clinical Science (London, England : 1979)|June 25, 2017
AT1-receptor blockade attenuates outward aortic remodeling associated with diet-induced obesity in miceFriedrich Krueger, Kai Kappert, Anna Foryst-Ludwig, et al.
Pageof 2